Ventana Medical Systems,a member of the Roche Group, and pharmaceutical company Boehringer Ingelheim (BI) have entered into a collaboration agreement for the development of companion diagnostic tests for BI oncology programs. Companion ...
Cancer Research Technology (CRT), Cancer Research UK's technology development arm, has signed a multi-project alliance agreement with Teva Pharmaceutical Industries (TEVA) to research and develop new cancer drugs, which will help in ...
US-based DiscoveRx’s BioSeek division launched BioMAP panel, a primary human cell-based assay platform, for oncology research. The BioMAP panel comprising primary human cell-based tumor-host model systems allows the researchers to ...
Tags: Oncology Research, Biomap Panel
Champions Oncology (Champions), a developer of advanced technology solutions and services to personalize the development and use of oncology drugs, has signed a new discovery and drug development partnership with Teva Pharmaceutical ...
Tags: Champions Oncology
Celgene has received approval from the US Food and Drug Administration (FDA) for its drug 'Abraxane' to treat patients with late-stage adenocarcinoma of the pancreas. Adenocarcinoma is a sub-type of exocrine tumors which accounts for ...
Molecular diagnostic company Myriad Genetics has launched myRisk Hereditary Cancer, a new multi-gene diagnostic test for hereditary cancer testing. The new test analyses 25 genes that are associated with breast, colorectal, ovarian, ...
Tags: Multi-Gene Test, Medicine
Japanese drugmaker Otsuka Pharmaceutical has agreed to acquire Astex Pharmaceuticals for $866m in an all-cash tender offer. Under the deal, Astex's fragment-based drug design technology called 'PYRAMID' will be integrated into Otsuka, ...
Therapeutic antibodies developer AnaptysBio has expanded its proprietary immunotherapy antibody portfolio to add multiple new combination therapies. The company developed a proprietary anti-PD-1 antibody, called ANB011, with key ...
Tags: AnaptysBio, Antibody Portfolio
Biotechnology company Amgen has reached a deal to buy all outstanding shares of California-based Onyx Pharmaceuticals for $125 per share in cash. The purchase price of the transaction that is expected to be closed by the beginning of ...
Tags: Amgen, Onyx Pharmaceuticals
PFM Medical, a developer and manufacturer of minimally invasive medical devices for cardio vascular technology, vascular access, surgery, and oncology, has received the US Food and Drug Administration (FDA) premarket approval for its ...
Tags: PFM Medical, Medicine
Israel-based ultrasound technology provider InSightec has received the approval from Health Canada for its ExAblate system designed to treat uterine fibroids and pain palliation of bone metastases non-invasively. The third generation ...
Tags: InSightec, ExAblate System
Johnson & Johnson has completed the acquisition of Aragon Pharmaceuticals, a pharmaceutical discovery and development company focused on drugs to hormonally-driven cancers. The Janssen Research & Development will manage compound ...
Accuray has announced its plans to tap the radiation oncology market in China with the introduction of its CyberKnife and TomoTherapy systems. The CyberKnife and the TomoTherapy systems give clinicians in China the most flexible treatment ...
Tags: Tomotherapy Systems, Cyberknife
The European Commission has granted additional indication for GlaxoSmithKline’s (GSK) Tyverb (lapatinib) in combination with trastuzumab for adult patients with overexpress HER2 (ErbB2), with hormone receptor-negative (HR-) metastatic ...
Tags: European Commission
GlaxoSmithKline (GSK) has submitted an application seeking approval from the European Medicines Agency (EMA) of a variation for Votrient (pazopanib). The approval is for additional indication for Votrient as the maintenance treatment of ...